Redeye comments on Vertiseit’s Q1 reporting, showing solid FX-adjusted ARR growth but somewhat soft ...
Rec PTP -2% vs ABGSCe, driven by higher property costs Vacancies up slightly, property values flat S...
Redeye provides its initial take on OEM’s Q1 2025 report, which came in slightly below our estimates...
Utvecklingen inom portföljbolagen visar fortsatt på en bra utveckling under det första kvartalet.
Redeye provides a comment following Magle Group’s announcement of the acquisition of Swedish medtech...
Redeye comments briefly on Insplorion’s Q1 report which was very much in line with our expectations.
Redeye comments on Powercell’s Q1 report which was mainly in line with our expectations.
Following low volumes in the previous Q4, Hansa’s Q1 is well above the rolling 12m average, and the ...
Net sales and EBIT were below market consensus (LSEG) in Q1.
Vitrolife faces a tough start in 2025, and we expect this to continue during H1 2025.
Q1 sales 3% below our ests. at SEK 207m, for -2.3% org.
Sales +6% and EBIT -8% vs. ABGSCe Order bookings 11% better than ABGSCe Slightly positive consensus ...
Redeye comments on Fortnox’s Q1, with the key figures matching our expectations.
Redeye sees a softer-than-anticipated Q1 report from Stille, with sales and EBIT falling below our f...
Redeye comments on Polygiene Group´s Q1 2025. Polygiene Group delivered positive growth of 18% YoY w...
As expected, Q1 is a modest quarter after an extended period of high organic growth.
Redeye comments on Lime’s Q1 report, with key figures missing our forecasts slightly.
Fiskars Q1 adjusted EBIT of EUR 26.8m came 1% above Modular Finance consensus expectations.
Redeye updates its outlook on Nanologica, continuing to anticipate a considerable sales ramp-up in H...
Atria reported Q1 adjusted EBIT of EUR 12.8m, 31% (EUR 3.
